



Evaluation of Fetuin-A and Antioxidant Levels in Breast Cancer Patients

Thamer Karim Jumaa Al-Saeedi, Abdulsalam Tawfeeq Salih Alsamarai, Ahmed Zuhair Al-Samarrai

1. University of Samarra, college of education

2. University of Samarra, college of applied Science

3. Oncology Teaching Hospital Baghdad Medical City

Abstract

The current study was conducted on (90) samples from a sample of women with breast disease. And G2 included 30 samples of breast-infected women who used the treatment. And the control group (the healthy ones) had (30) blood samples. The ages of the groups ranged between (25-74) years, as pictures were collected from the cancerous tumors hospital of a city in Baghdad governorate, between 1/1/2022 to 1/1/2023. after which the serum was obtained, then it was placed in small test tubes and kept in the refrigerator at a temperature of -20°C for the purpose of measuring the levels of Fetuin -A, antioxidants and some minerals to know their effect on patients with breast cancer.

The results of the current research showed that there was a significant increase in the blood serum of group G1, with a decrease in the serum of group G2 in the serum of Fetuin -A patients compared with the control group, with a significant decrease in the level of glutathione in the serum of all groups. While the level of malondialdehyde increased significantly ($P \leq 0.05$) in the serum of group G1 and G2 compared with healthy subjects, and calcium showed no significant differences in the serum of all groups.

Key words / Breast cancer , Fetuin -A, antioxidant , Calcium.

Introduction

Breast cancer is a life-threatening disease that may affect a woman's sense of self-respect, self-love, and her sense of femininity ⁽¹⁾. Breast cancer is the most common non-cutaneous malignant tumor ⁽²⁾. Which carries milk to the nipple ⁽³⁾, it occurs in women and men, but the percentage of infection in women is very large compared to males, as every 200 infection in women corresponds to one infection in men ⁽⁴⁾.

Breast cancer is a group of diseases that result in lumping as a result of abnormal changes and divisions in the cells of the breast tissue ⁽⁵⁾. It is a multifaceted disease with both environmental and genetic causes and shows a large degree of heterogeneity between and within tumors ⁽⁶⁾. Breast cancers most often begin in the

milk glands (lobules) or in the ducts that connect the lobules to the nipple ^(8,7).

No symptoms appear in the first period of breast cancer through which breast cancer can be distinguished, because the tumor is small, but when the size of the tumor grows, it can be felt through (its size) ⁽⁹⁾, a change in the skin of the breast and fluid secretion from the nipple ⁽¹⁰⁾, And among the factors that develop breast cancer is a change in the sequence of nitrogenous bases, or it may be genetic reasons, but there is a mutation of 5-10 that is inherited from the parents, or the mutation may be a result of aging or the result of surrounding factors, and these factors can cause genetic abnormalities in the cell ⁽¹¹⁾.

Fetuin -A is a glycoprotein that belongs to the cysteine superfamily of protease inhibitors ⁽¹²⁾. As it has a molecular weight

of 52 kDa, it is synthesized mostly by the liver and is later excreted into the bloodstream. High amounts of Fetuin were described in fetal calf serum and showed that its concentration decreases with the age of the animal ⁽³¹⁾.

Fetuin-A protein has a close relationship with the development of heart disease and arteries ⁽¹⁴⁾, and it was found to have a significant increase in patients with myeloma compared to healthy subjects ⁽¹⁵⁾. As well as its relationship to Diabetes mellitus, Kidney, Cancer and inhibition of ectopic calcification ⁽¹⁶⁾. Fetuin was also found to be associated with breast cancer ⁽¹⁷⁾.

Antioxidants have a role in breast cancer, as glutathione is involved in many metabolic processes, and its deficiency leads to cellular risk as a result of oxidative damage ⁽¹⁸⁾. It was found that disturbances in the balance of the oxidized form and the reduced form of glutathione have an important role in tumor initiation and development, and may have an important role in the extent of response to treatment ⁽¹⁹⁾.

In addition, oxidative stress is the state in which the concentration of free radicals increases. Therefore, these radicals are very effective as they interact with the components of the cell, the most important of which are the nucleic acids that form an important part of the cell nucleus, leading to the oxidation of these acids and bringing about changes that may be repairable within the biological system ⁽²⁰⁾. Malonaldehyde is an indicator of oxidative stress as well as the incidence of some diseases, as the MDA level rises in women with breast cancer, and it rises in patients after radiotherapy ⁽²¹⁾.

In addition, calcium may contribute to the formation of breast cancer, as it was found

that the high level of calcium in postmenopausal women could lead to breast cancer ⁽²²⁾. Since the increase of Fetuin -A and oxidative stress in the human body may be threatening to the immune system and thus exposure to breast cancer, therefore, the current research aimed to evaluate the level of Fetuin -A and antioxidants in patients with breast cancer.

Material and Methods

Study Samples:

The current study was conducted on (90) blood samples, which were divided into three groups:

- **G1 included 30 samples from women with breast cancer.**
- **G2 included 30 samples of women with breast cancer who took a single dose of treatment.**
- **The control group (the healthy ones) had (30) blood samples.**

The ages of the groups ranged between (25-74) years, as the samples were collected from the cancerous tumors hospital affiliated to the Medical City in Baghdad Governorate, for the period between 1/1/2022 to 1/1/2023. Where he collected about 5 cm³ of blood from patients and healthy people, and the samples were divided according to the type of test, after placing them in Jell tubes with a tight cover and free of anticoagulant and leaving the blood at a temperature of 25 °C until it coagulated and then placed in a centrifuge for a period of time. 10 minutes at a speed of 3000 cycles / minute, after which the serum was obtained, then it was placed in small test tubes and kept in the refrigerator at a temperature of -20 ° C for the purpose of measuring the levels of antioxidants, Fetuin -A and some

minerals to know their effect on breast cancer.

-Estimation of Fetuin_A levels in the blood serum

The concentration of Fetuin_A in the serum was estimated through a ready-made assay kit. The ELISA technique is an enzyme-linked immunoassay in the solid phase based on the principle of competitive binding, as the holes of the plate covered with the Fetuin_A antibody are incubated with the Fetuin_A present in the serum and the Incubation Diluent (INC-BUF) in Room temperature with stirring. During the incubation period, a fixed amount of Fetuin_A conjugated with Fetuin_A competes in the serum of the sample to observe a specific number of binding sites on the antibody to Fetuin_A, and then we wash the pits, and after the washing step, detection is made. The conjugate Fetuin_A with conjugate (ENZ-CONJ) and specimen Diluent (SAM-DIL). The conjugation of ENZ-CONJ and the etch-bound SAM-DIL is gradually accompanied by an increase in LH concentration, and after waiting an hour the unbound ENZ-CONJ and SAM-DIL are removed and the pits are washed after. Then a chromogenic solution is added and incubated at room temperature with stirring for 15 minutes, which leads to the appearance of a blue color, then the color turns yellow by adding a stop solution. A standard curve is obtained by plotting the concentration of the standard against the absorbance. The intensity will be. The color is directly proportional to the amount of Fetuin_A in the sample.

-Estimation of GSH and MDA level in the blood serum

The level of antioxidants represented by (glutathione, malondialdehyde) was estimated, as the ELISA technique was used to measure the level of antioxidants according to the ELISA Sandwich technique, as the Microelisa plate for each was coated with the appropriate antibody (GSH.MDA), after which the standard solution or samples were added to Etch the appropriate Microelisa stripplate and conjugate it with the specific antibody, then add the glutathione-specific HRP-Conjugate reagent and Malone dialdehyde to each hole of the Microelisa plate well and incubate it, and then it is washed well and then add chromogen solution A, B the color of the liquid will turn blue. After adding the stop solution, the color turns yellow, and then the absorbance is measured at a wavelength of 450 nm, as the value of the intensity of the absorbance is proportional to the concentrations of glutathione and malondialdehyde in blood serum ^(23,24).

-Estimation of Calcium level in the blood serum

The concentration of calcium in blood serum was measured according to the ready-made assay kit by the Spanish company LiNER ⁽²⁵⁾, as the method depends on the interaction of calcium with the red complex compound as a complex component in the basic solution Ocresol phtaleine in which we measure the concentration of calcium.

Statistical analysis:

The statistical program SPSS was used to analyze the results obtained, if the arithmetic mean and the standard deviation SD were used for the data under study, and the T-test was used to compare the biochemical variables between the two groups of patients and control at the level of probability $P \leq 0.05$.

Results and discussion:

- Measurement of the levels of biochemical variables for the samples under study:

Table (1): shows the mean - standard deviation of the biochemical variables of the samples under study

Parameters	Mean \pm S.D			P
	Control	G1	G2	
Fetuin-A ng/ml	54.643 \pm 11.449c	103.605 \pm 14.434b	127.140 \pm 21.425a	≤ 0.05
GSH(ng/ml)	8.206 \pm 1.082a	3.812 \pm 0.430b	3.986 \pm 1.066b	≤ 0.05
MDA (ng/ml)	5.486 \pm 1.607c	13.962 \pm 2.956b	19.976 \pm 5.565a	≤ 0.05
Ca(mg/dl)	8.749 \pm 0.323a	8.022 \pm 0.319c	8.252 \pm 0.408b	≤ 0.05

Significant $P \leq 0.05$

- The different letters indicate the presence of significant differences, but the similar ones, there are no significant differences.
- G1 refers to the group of women with breast cancer without a dose.
- G2 refers to the group of women diagnosed with breast cancer for a single dose.

-Estimation of the Fetuin-A in the blood serum

Table (1-1) shows the average \pm standard deviation of the fatwain level, as it reached (54.643 \pm 11.449) ng / ml in patients of the first group G1 and (103.605 \pm 14.434) ng / ml in patients in group G2, compared to (127.140 \pm 21.425) ng/ml in healthy women in the control group. The results showed that there was a significant increase in the level of fatwain in the blood serum of groups G1 and G2 compared to healthy women and at the level of probability ($P \leq 0.05$).




Figure (1): The level of the Fetuin-A in the blood serum of the samples under study

Cigdem (26) indicated in his study that there were no significant differences in the

level of Fetuin in patients with breast cancer in the early stages of infection, so

he concluded in his study that he did not find any correlation between the levels of Fetuin and patients, and it was found that Fetuin -A is an important marker in the microenvironment tumorigenic CSCs and metalloproteinases ^(27, 28). Fetuin-A was found to be a biomarker in the serum of colorectal cancer patients ⁽²⁹⁾. Moreover, a study conducted in Mexico in breast cancer patients found that autoantibodies in the blood against fetuin-A protein were useful as serum biomarkers for early-stage breast cancer screening ⁽³⁰⁾. So it appears that Fetuin-A is a chemoattractant in the blood that also promotes the invasion of breast cancer tumor cells ⁽³¹⁾.

On the other hand, a study in a rat model reported that deficiency in Fetuin -A may reduce PyMT transgenic breast cancer tumors by more than 60% ⁽³²⁾. Because Fetuin -A is an abundant serum protein, it

is considered an important factor of metastasis in breast cancer in humans. It has been reported that Fetuin -A deficiency resulted in failure of breast tumor development in murine models ⁽³³⁾.

- Estimation of GSH level in blood serum:

Table (1-1) shows that the mean \pm standard deviation of the glutathione level was (3.812 ± 0.430) nanomoles / liter in patients with the first group (G1) and 3.986 ± 1.066 n mol / L in patients with the second group (G2), compared to (8.206 ± 1.082) nanomoles / L in healthy women, the results showed a significant decrease in the level of glutathione in the blood serum of groups G1, G2, compared to the healthy group, at a probability level ($P \leq 0.05$), as in Figure (2).




Figure (2): The average level of GSH in the blood of the samples under study

Through the results, we notice a decrease in the level of glutathione in patients with breast cancer, so the results of the current study agree with the findings of Enrico ⁽³⁴⁾ and Luke ⁽³⁵⁾. In the forms of reduced glutathione and oxidized glutathione, the

processes of glutathione synthesis, transport, utilization, and metabolism are tightly controlled to maintain intracellular glutathione and redox homeostasis ⁽³⁶⁾. As for cancer cells, they need a greater level of ROS than normal cells. To promote

excessive metabolism and reproduction ^(37, 38).

Fatemeh ⁽³⁹⁾ indicated that patients with breast cancer who were treated with chemotherapy Adriamycin at a concentration of 60 mg / m² and Cytosan at a concentration of 600 mg / m² showed that the results after 3 cycles of chemotherapy showed a decrease in the concentration of antioxidants, so it was found that chemotherapy in breast cancer patients It may lead to radical changes in the levels of the oxidation system / antioxidants in the body. The decrease in glutathione levels in group G1 and G2 is due to its depletion as a result of oxidative stress caused by cancer cells in G1 and due to chemotherapy in group G2.

On the other hand, it was found through the results also that there was a decrease in glutathione levels in patients with breast cancer as a result of taking treatment, as it was noted that there was a relationship between an increase in the level of glutathione and resistance to chemotherapy in many types of cancer ⁽⁴⁰⁾. A weakened antioxidant defense system, including glutathione, can sensitize cancer cells to

current chemotherapy treatments. As well as a moderate decrease in the level of GSH would be an effective strategy to improve the sensitivity of cancer cells to chemotherapies. Therefore, depletion of cellular GSH in cancer cells will make them more vulnerable and sensitive to oxidative stress and chemotherapy. Cysteine insufficiency, glutamate insufficiency, or pharmacological and genetic inhibition of the system can also reduce the resistance of cancer cells to chemotherapies ⁽⁴¹⁾.

-Estimation of the MDA level in the blood serum

Table (1 shows that the mean \pm standard deviation of the malondialdehyde level was $(13.962 \pm 2.956) \mu\text{mol} / \text{L}$ in patients of the first group G1 and $(19.976 \pm 5.565) \mu\text{mol} / \text{L}$ in patients of the second group G2, compared to $(5.486 \pm 1.607) \mu\text{mol/L}$ in healthy women.

The results showed a significant increase in the level of malondialdehyde in the blood serum of groups G1 and G2, compared to the healthy group, at a probability level ($P \leq 0.05$), as in Figure (3).




Figure (3): The level of MDA in the blood serum of the samples under study

The results showed a significant increase in the level of malondialdehyde in patients with breast cancer compared with the group of healthy women, as the results of the current study agree with the results of Lilo and his group⁽⁴²⁾ and Khalaf and his group⁽⁴³⁾ Nsaif, , who showed in their study a high level of MDA in the serum of breast cancer patients compared with the control group. Maher (saad et al., 2020)⁽⁴⁴⁾ showed that serum MDA levels are a marker of lipid peroxidation caused by oxidative stress, as it was found in his study that malondialdehyde levels were significantly lower in healthy subjects compared to breast cancer patients.

MDA is one of the types of oxidative stress that is a major cause of the initiation and development of breast cancer and is often associated with a high risk of cancer, as its level is elevated in patients with breast cancer. It is commonly associated with vital metabolism-boosting antioxidants^(46,45). Therefore, the results also agree with what Araz⁽⁴⁷⁾ said.

Oxidative stress is an important and major factor for the development of cancer, as it is associated with the generation of reactive oxygen species for the development of cancer, as cancer cells show high levels of ROS and a strong regulation of redox homeostasis to maintain a low level of oxidative stress⁽⁴⁸⁾. On the other hand, the results showed a significant significant increase in the G2 group after taking the treatment, as the results of the current study agree with the results of Gupta and his group⁽⁴⁹⁾. And

those who showed in their study the high level of MDA in women with breast cancer after chemotherapy compared to a group of healthy women. While⁽⁵⁰⁾ indicated in his study that there was a decrease in the level of malondialdehyde during the different doses of treatment, including the first, second and third doses, and this is not consistent with the results of the current study.

The reason for the high level of MDA in group G2 may be attributed to the decomposition of the membranes of red blood cells as a result of the attack of unsaturated fats in them by free radicals. A study indicated that MDA levels increased in the serum of patients with breast and cervical cancer compared to healthy subjects. They attributed the reason for the increase in lipid peroxidation, which could be attributed to increased generation of reactive oxygen species or inhibition of the antioxidant defense mechanism in metabolically active tissues⁽⁵¹⁾.

-Estimation of the Calcium level in the blood serum

Table (1) shows that the mean \pm standard deviation of the calcium level was (8.022 ± 0.319) mg/dl in patients of the first group and 8.252 ± 0.408 mg/dl in patients of the second group (G2), compared to (8.749 ± 0.323) mg. / dl in healthy women, the results showed a significant decrease in the level of calcium in the blood serum of groups G1, G2 compared to the group of healthy women and at the level of probability ($P \leq 0.05$) as in Figure (4).




Figure (4) - The level of calcium in the blood of the samples under study.

It is clear from the above results that the level of calcium (Ca) decreased in women with breast cancer compared to the control group. The results of the current study agree with what the researchers Hutchison and Aziz^(53,52) said that the low level of calcium in the blood of women with breast cancer confirms what the researchers said that calcium is inversely associated with breast cancer^(52, 53). This protective effect can be explained by By increasing cellular calcium levels after an elevated blood calcium level, which may affect multiple cellular processes including cell cycle and cell death.

The results of the current study do not agree with the results of Hassan⁽⁵⁴⁾, who found an increased level of calcium concentration in women with breast cancer compared to the control group. Jasim and others⁽⁵⁵⁾ indicated that the level of calcium is high in women with breast cancer, especially if the cancer spreads to the bones, causing osteoporosis and releasing calcium into the blood, where cancer cells secrete themselves like parathyroid hormone, which increases

calcium absorption. And increase its concentration in the blood.

The higher calcium in the G2 group may be evidence of a protective effect of calcium against breast cancer mostly from observational studies evaluating dietary calcium intake⁽⁵⁶⁾. Controlled trials showed that calcium supplementation did not reduce the overall risk of benign proliferative breast disease, a precursor to breast cancer, in postmenopausal women⁽⁵⁷⁾. To confirm the proposed protective effect of calcium against breast cancer, it has been shown that circulating calcium, which is involved in many cellular processes⁽⁵⁸⁾.

References

- 1-Ebrahim, S. Knowledge of students toward breast cancer and breast self-examination practice at high school nursing in Basra city. Rev J Kufa for Nurs Sci 4.1 (2014): 0-0.
- 2-Yedjou, Clement G., et al. "Health and racial disparity in breast cancer." Breast cancer metastasis and drug resistance 2019. 31-49.

- 3-Sariego, Jack. "Breast cancer in the young patient." *The American surgeon* 76.12 (2010): 1397-1400.
- 4-Jemal, Ahmedin, et al. "Cancer statistics, 2010." *CA: a cancer journal for clinicians* 60.5 2010; 277-300.
- 5-Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B. and Luo, W. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes and diseases*, 2018; 5 (2):77-106.
- 6-Yeo, S. K. and Guan, J.-L. Breast cancer: multiple subtypes within a tumor? *Trends in cancer*, 2017; 3 (11):753-760.
- 7-Testa, U., Castelli, G. and Pelosi, E. Breast cancer: a molecularly heterogenous disease needing subtype-specific treatments. *Medical Sciences*, 2020; 25(1):115-121.
- 8-American Cancer Society. Breast cancer facts & figures (2019-2020). *Am. Cancer Soc.* 17:1-44.
9. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A. American cancer society/American society of clinical oncology breast cancer survivorship care guideline. *CA: a cancer journal for clinicians*. 2016;66(1):43-73.
- 10-Kim MJ, Park BW, Lim JB, Kim HS, Kwak JY, Kim SJ, Park SH, Sohn YM, Moon HJ, Kim EK. Axillary lymph node metastasis: CA-15-3 and carcinoembryonic antigen concentrations in fine-needle aspirates for preoperative diagnosis in patients with breast cancer. *Radiology*. 2010;254(3):691-7.
- 11-Anand P, Kunnumakara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B, Aggarwal BB. Cancer is a preventable disease that requires major lifestyle changes. *Pharmaceutical research*. 2008 Sep;25(9):2097-116.
- 12-Komsa-Penkova, R.S.; Golemanov, G.M.; Radionova, Z.V.; Tonchev, P.T.; Iliev, S.D.; Penkov, V.V. Fetuin-A—Alpha2-Heremans-Schmid Glycoprotein: From Structure to a Novel Marker of Chronic Diseases Part 1. Fetuin-A as a Calcium Chaperone and Inflammatory Marker. *J. Biomed. Clin. Res.* 2018, 10, 90–97.
- 13-Alkanaani MI, Rajab ER, Abdulwahed AM, Dabos T, Alshammiri B, Abdullah SN, Al-Samarraie MQ. Visfatin hormone level and lipid profile in some hyperlipidemia patients in samarra city. *Biochem. Cell. Arch.* 2020;20(1):1191-3.
- 14- Nascimbeni, F.; Romagnoli, D.; Ballestri, S.; Baldelli, E.; Lugari, S.; Sirotti, V.; Giampaoli, V.; Lonardo, A. Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease? *Diseases* 2018, 6, 17.
- 15-Ali S. Salman , Eman S.Salaha and Mohammed S.Abass. Estimation of Beta Two Microglobulins, Fetuin-A, Resistin Serum Level in Iraqi Multiple Myeloma Patients. *Iraqi J Pharm Sci*, . 2020 ;.29(2).
- 16-Josiah Ochieng,, Gladys Nangami, Amos Sakwe, Cierra Moye, Joel Alvarez,1 Diva Whalen,1 Portia Thomas,1 and Philip Lammers. Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes . *Int J Mol Sci.* 2018; 19(8): 2211.
- 17-Abdulwahed AM, Alkanaani MI, Alsamarrai AH, Hamad MA, Dakheel A, Al-Samarraie MQ. Determination of some visfatin hormone level and lipid

- profilein some breast cancer patients in Samarra city. *Annals of Tropical Medicine and Health*. 2020;23:265-7.
18. Teskey, G., Abraham, R., Cao, R., *et al* . Glutathione as a marker for human disease. *Advances in clinical chemistry*, 2018; 87: 141-159.
 19. Diotallevi M, Checconi P, Palamara AT *et al*. Glutathione fine-tunes the innate immune response toward antiviral pathways in a macrophage cell line independently of its antioxidant properties. *Frontiers in immunology*. 2017;1239.
 20. Ruan, X., Sun, Y., Du, W., Tang, Y., Liu, Q., Zhang, Z., Tsang, D. C. Formation, characteristics, and applications of environmentally persistent free radicals in biochars: a review. *Bioresource technology*. 2019; 281:457-468.
 - 21- Youssef, Hanan, and Hala Salem. "Oxidative stress parameters in patients with breast cancer before and after radiotherapy." *Egyptian Journal of Radiation Sciences and Applications* .2019; 32.2: 177-185.
 - 22-Linda, H., Vanessa, A. F., & Veronica, A. M. (2004). Calcium Supplement Guidelines. University faculty. *california.arizona.edu/pubs/health/az1042*.
 - 23- Pompella, A; Visvikis, A; Paolicchi, A; Tata, V; Casini, AF .2003.
 - 24- Pryor WA, Stanley JP .1975.
 - 25- Connerty, H.V. y Biggs, A.R. *Am. J. Clin. Path.* 45 : 290 (1966).
 - 26-Cigdem Usul Afsar¹, Hale Aral², Orçun Can¹, Didem Can Trabulus³, Didem Karacetin⁴, Mehmet Ali Nazlı⁵, Rıza Umar Gursu⁶, Senem Karabulut⁷
SERUM FETUIN-A AND RANKL LEVELS IN PATIENTS WITH
EARLY STAGE BREAST CANCER .J Med Biochem 2023; 42 DOI: 10.5937
 27. Ochieng J, Nangami G, Sakwe A, Moyo C, Alvarez J, Whalen D, *et al*. Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes. *Int J Mol Sci* 2018; 19(8): E2211.
 28. Dong Y, Ding D, Gu J, Chen M, Li S. Alpha-2 Heremans Schmid Glycoprotein (AHSG) promotes the proliferation of bladder cancer cells by regulating the TGF- β signalling pathway. *Bioengineered* 2022; 13(6): 14282–98.
 - 29- Fan NJ, Kang R, Ge XY, Li M, Liu Y, Chen HM, *et al*. Identification α 2-HS glycoprotein precursor and tubulin β -chain as serology diagnosis biomarker of colorectal cancer. *Diagn Pathol* 2014; 9: 53.
 - 30- Fernández-Grijalva AL, Aguilar-Lemarroy A, Jave-Suarez LF, Gutiérrez-Ortega A, Godínez-Melgoza PA, Herrera-Rodríguez SE, *et al*. Alpha 2HS-glycoprotein, a tumorassociated antigen (TAA) detected in Mexican patients with early-stage breast cancer. *J Proteomics* 2015; 112: 301–12.
 - 31-Nangami GN, Watson K, Parker-Johnson K, Okereke KO, Sakwe A, Thompson P, *et al*. Fetuin-A (α 2HS-glycoprotein) is a serum chemo-attractant that also promotes invasion of tumor cells through Matrigel. *Biochem Biophys Res Commun* 2013; 438(4): 660–5.
 - 32- Guillory B, Sakwe AM, Saria M, Thompson P, Adhiambo C, Koumangoye R, *et al*. Lack of fetuin-A (α 2-HS-glycoprotein) reduces mammary tumor incidence and

- prolongs tumor latency via the transforming growth factor-beta signaling pathway in a mouse model of breast cancer. *Am J Pathol.* 2010 Nov;177(5):2635-44.
33. Watson K, Koumangoye R, Thompson P, Sakwe AM, Patel T, Pratap S, et al. Fetuin-A triggers the secretion of a novel set of exosomes in detached tumor cells that mediate their adhesion and spreading. *FEBS Lett.* 2012 Sep 21;586(19):3458-63.
 - 34- Enrico Desideri , Fabio Ciccarone et al. Targeting Glutathione Metabolism: Partner in Crime in Anticancer Therapy. *Nutrients* 2019, 11(8), 1926.
 - 35-Luke Kennedy Jagdeep K. Sandhu et al. Role of Glutathione in Cancer: From Mechanisms to Therapies. *Biomolecules* 2020, 10(10), 1429.
 - 36- Huanhuan Lv , Chenxiao Zhen.et al. Unraveling the Potential Role of Glutathione in Multiple Forms of Cell Death in Cancer Therapy. Volume 2019 |Article ID 3150145 | <https://doi.org/10.1155/2019/3150145>.
 - 37-MOLONEY, Jennifer N.; COTTER, Thomas G. ROS signalling in the biology of cancer. In: *Seminars in cell & developmental biology.* Academic Press, 2018: 50-64.
 - 38-GALADARI, Sehamuddin, et al. Reactive oxygen species and cancer paradox: to promote or to suppress?. *Free Radical Biology and Medicine*, 2017, 104: 144-164.
 - 39-Fatemeh Pakmanesh, Daryoush Moslemi, MD,² and Soleiman Mahjoub, PhD^{3,4} Pre and post chemotherapy evaluation of breast cancer patients: Biochemical approach of serum selenium and antioxidant enzymes . *Caspian J Intern Med.* 2020 Autumn; 11(4): 403–409.
 - 40- CHEN, Helen HW; KUO, Macus Tien. Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. *Metal-based drugs*, 2010, 2010.
 - 41- ROH, Jong-Lyel, et al. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. *Cancer letters*, 2016, 381.1: 96-103.
 - 42-LILO, Rafal Ahmed; ALI, Rasha Nayyef. Evaluation of the oxidative state of women with breast cancer in AL-Hilla city. *Basic Education College Magazine For Educational and Humanities Sciences*, 2020, 48.
 - 43-KHALAF, Mohammed Yaseen, et al. The correlation of antioxidant levels of breast cancer: A case controlled study. *Medicine*, 2021, 100.35.
 - 44-Saad, M. E., El-mezayen, H., Refaa, S., Tahmasebpour, N., Feizi, M. A. H., Ziamajidi, N., Pouladi, N., Montazeri, V., Farhadian, M., & Abbasalipourkabir, R. (2020). Association of omentin-1 with oxidative stress and clinical significances in patients with breast cancer. In *Advanced Pharmaceutical Bulletin* 10(1): 106–113.
 - 45-Bratt D, Kh J, Patel S, Zaveri M. Role of oxidative stress in breast cancer. *Pharm Pharmaceu Sci* 2016;5:366–79.
 - 46- NSAIF, Ghufra Saad, et al. Evaluation of Estradiol and Some Antioxidant in Breast Cancer Iraqi Women. *Al-Nahrain Journal of Science*, 2018, 21.1: 35-40.
 - 47-Araz Yousif Revision of some Biomarkers with Cytokines in Breast Cance Baghdad Science Journal. 2023, 20(1): 26-31.
 - 48-Lij Zou. Significant Role of Antioxidants in the Treatment of Breast

- Cancer . Oxidants and Antioxidants in Medical Science, 2022 . VOL 11, NO. 6, PAGE 01 .
- 49- GUPTA, Rakesh Kumar, et al. Interactions between oxidative stress, lipid profile and antioxidants in breast cancer: a case control study. Asian Pacific Journal of Cancer Prevention, 2012, 13.12: 6295-6298.
 - 50- Tarteel Amjed Hamza Hassan Al-Fatla. Study of Antioxidants, Homocysteine, Cytokines in Different Grads of Breast Cancer Patients. A Theses Submitted to the Council of the College of Science for Woman, University of Babylon in Partial Fulfillment of the Requirements for the Degree of Master of Science in Chemistry. 2022.
 - 51- ENDO, Motoyoshi, et al. Serum ANGPTL2 levels reflect clinical features of breast cancer patients: implications for the pathogenesis of breast cancer metastasis. The International journal of biological markers, 2014, 29.3: 239-245.
 52. Hutchison, A. J. Oral phosphate binders. Kidney international, 2009. 75(9), 906-914.
 53. Aziz Mahmood, A., Masood Bilal, K., & Talib Ibrahim, R. Influence of some Trace Elements and Biochemical Parameters on Breast Cancer. JOURNAL OF EDUCATION AND SCIENCE, 2012; 25(1), 34-43.
 54. Arooj, B., Ahmed, S., Saleem, M., Khurshid, R. and Zia, M., Serum trace elements in diagnosis of breast malignancy. Jour. of Ayub Med. College Abbottabad, 2012; 24(2), 62-64.
 55. Jasim, R.Z., Estimated some Antioxidant Enzymes and Trace Elements in some Iraqi Women Infected with Breast Cancer. 2016.
 56. Chen, P., Hu, P., Xie, D., Qin, Y., Wang, F., & Wang, H. (2010). Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast cancer research and treatment, 121(2), 469-477.
 57. Cullen, P. J., & Lockyer, P. J. Integration of calcium and Ras signalling. Nature reviews Molecular cell biology, 2002; 3(5), 339-348.
 58. Zainab Ahmad Hasaan (2011). Study of physiological , biochemical and hormones of women affected by breast cancer in Kirkuk city , College of Science – Tikrit University. 2011.